197 – Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Background Data on antiretroviral therapy (ART) outcomes in persons who acquire HIV with long-acting cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) are limited. We evaluated ART outcomes in CAB-LA exposed cisgender men and transgender women who have sex with men (MSM/TGW) who acquired HIV in the HPTN 083 trial. ART regimens were selected at study sites; local…